Free tool
Drug Trial Radar
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 19, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
3,690
Active, not recruiting, industry sponsors
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting7,024
- Not yet recruiting2,256
- Completed64,782
3,690 trials
Showing 1 to 25, recently updated first.
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05397496 · 61 participants · Start Oct 3, 2022 · Primary completion May 31, 2027
Drug: PIT565 · For: B-cell Non-Hodgkin Lymphoma (B-NHL); B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Miami, Florida; Chicago, Illinois; Fairway, Kansas · 18 sites in all
- A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving DupilumabActive, not recruiting
SanofiSanofi (SNY)
NCT06169527 · 303 participants · Start Nov 28, 2023 · Primary completion Jul 5, 2028
Drug: Dupilumab · For: Atopic Dermatitis
Sites: Amiens, France; Angers, France; Argenteuil, France · 42 sites in all
- A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsPivotal-lookingActive, not recruiting
IpsenIndustry
NCT07435428 · 1,305 participants · Start Feb 18, 2026 · Primary completion Sep 28, 2026
Drug: Corabotase; Placebo · For: Moderate to Severe Glabellar Lines
Sites: Los Angeles, California; Newport Beach, California; Pasadena, California · 60 sites in all
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersPivotal-lookingActive, not recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05152147 · 920 participants · Start Dec 2, 2021 · Primary completion Jul 15, 2026
Drug: Zanidatamab; Tislelizumab and 5 more · For: Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Pergamino, Argentina · 227 sites in all
- A Trial of SHR-1139 in Healthy VolunteersActive, not recruiting
Atridia Pty Ltd.Industry
NCT07078695 · 24 participants (planned) · Start Aug 19, 2025 · Primary completion Nov 9, 2026
Drug: SHR-1139 Injection; SHR-1139 Injection and 1 more · For: Psoriasis
Sites: Perth, Australia
- Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing TumorsActive, not recruiting
Orano Med Theranostics, SASIndustry
NCT05283330 · 48 participants · Start Dec 22, 2022 · Primary completion Jan 2027
Drug: ²¹²Pb-DOTAM-GRPR1 · For: Cervical Cancer; Breast Cancer; Colon Cancer and 4 more
Sites: Chicago, Illinois; Iowa City, Iowa; Lexington, Kentucky · 8 sites in all
- Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO DeficiencyPivotal-lookingActive, not recruiting
MedicureIndustry
NCT04706013 · 15 participants (planned) · Start Feb 16, 2024 · Primary completion Sep 2027
Drug: Pyridoxal Phosphate · For: Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Sites: Birmingham, Alabama; Palo Alto, California; Aurora, Colorado · 10 sites in all
- A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADPivotal-lookingActive, not recruiting
Annovis Bio Inc.Industry
NCT06709014 · 861 participants · Start Feb 4, 2025 · Primary completion Dec 2027
Drug: buntanetap/posiphen; Placebo · For: Early Alzheimers Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 78 sites in all
- A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsPivotal-lookingActive, not recruiting
IpsenIndustry
NCT07427797 · 309 participants · Start Feb 27, 2026 · Primary completion Aug 12, 2026
Drug: Corabotase; Placebo · For: Moderate to Severe Glabellar Lines
Sites: Birmingham, Alabama; Glendale, Arizona; Scottsdale, Arizona · 23 sites in all
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)Pivotal-lookingActive, not recruiting
Mirum Pharmaceuticals, Inc.Industry
NCT04663308 · 182 participants · Start Dec 18, 2020 · Primary completion Feb 20, 2026
Drug: Volixibat; Placebo · For: Primary Sclerosing Cholangitis
Sites: Coronado, California; Los Angeles, California; Sacramento, California · 103 sites in all
- A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy SubjectsActive, not recruiting
Shine-On Biomedical Co., Ltd.Industry
NCT07219940 · 15 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 2026
Drug: SOB100 · For: Healthy Subjects; Exosome; Targeted Therapy
Sites: Baltimore, Maryland
- Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's DiseaseActive, not recruiting
Lexeo TherapeuticsIndustry
NCT05400330 · 10 participants · Start May 8, 2023 · Primary completion Nov 2028
Drug: LX1001 · For: Alzheimer Disease
Sites: Orlando, Florida; Durham, North Carolina
- A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04035005 · 1,013 participants · Start Aug 12, 2019 · Primary completion Jan 15, 2025
Drug: Ocrelizumab; Placebo · For: Multiple Sclerosis, Primary Progressive
Sites: Washington D.C., District of Columbia; Clearwater, Florida; Orlando, Florida · 153 sites in all
- A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationActive, not recruiting
Astellas Pharma IncAstellas (ALPMY)
NCT06970665 · 17 participants · Start Jul 8, 2025 · Primary completion Jun 30, 2027
Drug: avacincaptad pegol · For: Geographic Atrophy; Age-Related Macular Degeneration
Sites: Fukushima, Japan; Kita-gun, Japan; Yokohama, Japan · 10 sites in all
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseasePivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06760637 · 1,037 participants · Start Jan 6, 2025 · Primary completion Jan 2, 2029
Drug: PF-07220060; letrozole and 3 more · For: Breast Cancer
Sites: Birmingham, Alabama; Chandler, Arizona; Gilbert, Arizona · 460 sites in all
- A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the BloodActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07781631 · 20 participants (planned) · Start Sep 10, 2026 · Primary completion Dec 14, 2026
Drug: Verducatib; Carbamazepine · For: Healthy
Sites: Berlin, Germany
- Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsPivotal-lookingActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT05215340 · 740 participants · Start Mar 4, 2022 · Primary completion Mar 4, 2030
Drug: Datopotamab Deruxtecan; Pembrolizumab · For: Metastatic Non Small Cell Lung Cancer
Sites: Chandler, Arizona; Los Angeles, California; Santa Barbara, California · 234 sites in all
- REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman SyndromePivotal-lookingActive, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT06914609 · 156 participants · Start Jun 10, 2025 · Primary completion Aug 2027
Drug: obudanersen; Placebo · For: Angelman Syndrome
Sites: Los Angeles, California; San Diego, California; Aurora, Colorado · 39 sites in all
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabActive, not recruiting
Syntrix Biosystems, Inc.Industry
NCT03161431 · 77 participants (planned) · Start Jun 12, 2019 · Primary completion Jul 31, 2026
Drug: SX-682; Pembrolizumab · For: Melanoma Stage III; Melanoma Stage IV
Sites: Miami, Florida; Boston, Massachusetts; Rochester, Minnesota · 6 sites in all
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05593094 · 210 participants (planned) · Start Sep 3, 2020 · Primary completion Aug 31, 2027
Drug: ZN-A-1041; ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b and 5 more · For: Advanced Solid Tumors; HER2-positive Breast Cancer
Sites: Tucson, Arizona; Cerritos, California; San Francisco, California · 36 sites in all
- A Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting ConditionsActive, not recruiting
Sichuan Huiyu Pharmaceutical Co., LtdIndustry
NCT07790562 · 88 participants (planned) · Start Jul 23, 2026 · Primary completion Sep 29, 2026
Drug: Ferric Derisomaltose Injection; Ferric Derisomaltose Injection [MonoFer®] · For: Iron Deficiency Anemia
Sites: Zhengzhou, China
- A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung CancerPivotal-lookingActive, not recruiting
CelltrionIndustry
NCT06939595 · 225 participants · Start Jan 30, 2025 · Primary completion Feb 2027
Drug: CT-P51; EU-approved Keytruda · For: Non Squamous Non Small Cell Lung Cancer
Sites: Tbilisi, Georgia
- A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06975722 · 105 participants · Start Jul 7, 2025 · Primary completion Dec 17, 2026
Drug: SAR442970; Placebo · For: Ulcerative Colitis
Sites: Fairhope, Alabama; Escondido, California; Lancaster, California · 61 sites in all
- A Trial of HRS-5965 Capsule in Primary IgA NephropathyPivotal-lookingActive, not recruiting
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07014826 · 389 participants · Start Jun 4, 2025 · Primary completion Oct 2027
Drug: HRS-5965; Placebo · For: Primary IgA Nephropathy
Sites: Beijing, China
- Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary ManifestationsActive, not recruiting
Xentria, Inc.Industry
NCT05890729 · 32 participants (planned) · Start Nov 10, 2023 · Primary completion Nov 30, 2026
Drug: XTMAB-16 or Placebo · For: Pulmonary Sarcoidosis
Sites: Birmingham, Alabama; Denver, Colorado; Jacksonville, Florida · 33 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.